αααααβααΎαAMRN β’ NASDAQ
add
Amarin Corporation PLC
14.72$
16 ααααΆ, 4:15:05 PM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·αααΆαααΈααααΆααααΆααααααΆααα
IE
αα·αααΈαα»α
15.20$
α
αααααααααααα
14.40$ - 15.15$
α
ααααααα½αααααΆαα
α»αααααα
8.84$ - 20.90$
ααΎαβαα»αβααΈααααΆα
304.84Β ααΆα USD
ααα ααα½αααΌαααααα
55.08Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 49.22Β ααΆα | -21.00% |
α
αααΆαααααα·ααααα·ααΆα | 25.43Β ααΆα | -40.80% |
α
αααΌααα»ααα | -1.22Β ααΆα | 97.48% |
ααααΆααα
αααααα»ααα | -2.49 | 96.81% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.01 | 102.50% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -1.56Β ααΆα | 89.82% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -43.66% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 302.59Β ααΆα | 2.84% |
ααααααααα»α | 670.78Β ααΆα | -2.13% |
ααΆαααα½ααα»αααααΌαααα»α | 211.49Β ααΆα | 6.19% |
ααΌαβααααα»α | 459.28Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 20.80Β ααΆα | β |
ααααααααααΉαααααα
| 0.69 | β |
ααα
ααααααΎαααααα | -0.85% | β |
ααα
ααααααΎααΎααα»α | -1.21% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -1.22Β ααΆα | 97.48% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 15.28Β ααΆα | 214.79% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -3.52Β ααΆα | 84.61% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -4.00ααΆαα | -123.53% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 11.76Β ααΆα | 132.54% |
ααα αΌαααΆα
αααααΆααααααα | 9.91Β ααΆα | -37.31% |
α’αααΈ
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
ααΆααααααΎαα‘αΎα
1 ααΈααΆ 1989
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
80
